Crizotinib in the management of advanced-stage non-small-cell lung cancer

Future Oncology

Volumn 11, Issue 5, 2015, Pages 735-745

  Loong, Herbert H ^a,b   Mok, Kevin ^a   Leung, Linda K S ^a,b   Mok, Tony S K ^a,b  

^a Prince of Wales Hospital   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

acquired resistance; brain metastases; c Met; crizotinib; EML4 ALK fusion; non small cell lung cancer; ROS1

Indexed keywords

CRIZOTINIB; PROTEIN TYROSINE KINASE; ANTINEOPLASTIC AGENT; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; ROS1 PROTEIN, HUMAN; SCATTER FACTOR RECEPTOR;

ADVANCED CANCER; ARTICLE; CANCER PATIENT; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; GENE ACTIVATION; GENE MUTATION; HUMAN; MAXIMUM PLASMA CONCENTRATION; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTO ONCOGENE; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CHEMISTRY; DISEASE MANAGEMENT; DRUG RESISTANCE; GENE AMPLIFICATION; GENETICS; LUNG NEOPLASMS; MORTALITY; PATHOLOGY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE MANAGEMENT; DRUG RESISTANCE, NEOPLASM; GENE AMPLIFICATION; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; ONCOGENE PROTEINS, FUSION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLES; PYRIDINES; TREATMENT OUTCOME;

EID: 84924813141     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.314     Document Type: Article

References (64)

1. Ferlay J, Soerjomataram I, Ervik M et al. Lung cancer estimated incidence, mortality and prevalence worldwide in 2012. In: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide. IARC Cancer Base No. 11. International Agency for Research on Cancer, Lyon, France(2013).
2. Palmer JD, Zaorsky NG, Witek M, Lu B. Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer. J. Thorac. Dis. 6, 387-398 (2014).
3. Mok TS, Wu Y-L, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947-957 (2009).
4. Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised Phase 3 trial. Lancet Oncol. 11, 121-128 (2010).
5. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380-2388 (2010).
6. Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, Phase 3 study. Lancet Oncol. 12, 735-742 (2011).
7. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase 3 trial. Lancet Oncol. 13, 239-246 (2012).
8. Sequist LV, Yang JC, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31, 3327-3334 (2013).
9. Wu YL, Zhou C, Hu CP et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised Phase 3 trial. Lancet Oncol. 15, 213-222 (2014).
10. Solomon BJ, Mok T, Kim DW et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 371, 2167-2177 (2014).
11. Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368, 2385-2394 (2013).
12. Zou HY, Li Q, Lee JH et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 67, 4408-4417 (2007).
13. Christensen JG, Zou HY, Arango ME et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol. Cancer Ther. 6, 3314-3322 (2007).
14. Bergethon K, Shaw AT, Ou SH et al. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol. 30, 863-870 (2012).
15. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566 (2007).
16. Fang DD, Zhang B, Gu Q et al. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib. J. Thorac. Oncol. 9, 285-294 (2014).
17. Takeuchi K, Choi YL, Togashi Y et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin. Cancer Res. 15, 3143-3149 (2009).
18. Bang YJ. The potential for crizotinib in non-small cell lung cancer: a perspective review. Ther. Adv. Med. Oncol. 3, 279-291 (2011).
19. Fan L, Feng Y, Wan H et al. Clinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-analysis. PLoS ONE 9, e100866 (2014).
20. Shaw AT, Ou SH, Bang YJ et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N. Engl. J. Med. 371, 1963-1971 (2014).
21. LP OD. Phase II safety and efficacy study of crizotinib in east Asian patients with ROS1 positive, ALK negative advanced NSCLC. Bethesda, MD, National Library of Medicine, USA (2014). www.clinicaltrials.gov
22. UNICANCER. Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1 (AcSé). Bethesda, MD, National Library of Medicine, USA (2014). www.clinicaltrials.gov
23. Camidge DR, Ou SI, Shapiro G et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). J. Clin. Oncol. 32(Suppl. 5), Abstract 8001 (2014).
24. Gandhi L, Janne PA. Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target. Clin. Cancer Res. 18, 3737-3742 (2012).
25. Yamazaki S, Vicini P, Shen Z et al. Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models. J. Pharmacol. Exp. Ther. 340, 549-557 (2012).
26. Ou SH. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond. Drug. Des. Devel. Ther. 5, 471-485 (2011).
27. McDermott U, Iafrate AJ, Gray NS et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. 68, 3389-3395 (2008).
28. Davies KD, Le AT, Theodoro MF et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin. Cancer Res. 18, 4570-4579 (2012).
29. Xu H, O'Gorman M, Boutros T et al. Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects. J. Clin. Pharmacol. 55(1), 104-113 (2015).
30. Li C, Alvey C, Bello A et al. Pharmacokinetics (PK) of crizotinib (PF-02341066) in patients with advanced non-small cell lung cancer (NSCLC) and other sold tumors. J. Clin. Oncol. 29, e13065 (2011).
31. Forde PM, Rudin CM. Crizotinib in the treatment of non-small-cell lung cancer. Expert Opin. Pharmacother. 13, 1195-1201 (2012).
32. Tan W, O'Gorman M, Lanzalone S et al. Pharmacokinetics of crizotinib (PF-02341066), a dual ALK/c-MET inhibitor, following administration of multiple oral doses to patients with advanced ALK-positive non-small cell lung cancer in China. Presented at: Asia Pacific Lung Cancer Conference. Fukuoka, Japan, 26-28November 2012 (Abstract 538).
33. French J, Tan W, Kang D et al. Preliminary exposure response (ER) analysis of crizotinib in patients with ALK-positive advanced non-small cell lung cancer. Presented at: American Society for Clinical Pharmacology and Therapeutics Annual Meeting. National Harbor, MD, USA, 12-17 March 2012.
34. Tan W, Wilner KD, Bang YJ et al. Pharmacokinetics of crizotinib (PF-02341066), a dual ALK/MET inhibitor, after multiple oral doses to advanced cancer patients. Presented at: American Society for Clinical Oncology Annual Meeting. Chicago, IL, USA, 4-8 June 2010 (Abstract 2596).
35. Research USFDAF-CFDEa. NDA 292570 Clinical Pharmacology Review - Crizotinib. Reference ID 2998079 Edition. 2011.www.accessdata.fda.gov
36. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).
37. Camidge DR, Bang YJ, Kwak EL et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a Phase 1 study. Lancet Oncol. 13, 1011-1019 (2012).
38. Ou SH, Bazhenova L, Camidge DR et al. Rapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancer. J. Thorac. Oncol. 5, 2044-2046 (2010).
39. Kim DW, Ahn MJ, Yang PC et al. Updated results of a global Phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer. Presented at: European Society for Medical Oncology Annual Congress. Vienna, Austria, 28September-2October 2012 (Abstract1230PD).
40. Shaw AT, Yeap BY, Solomon BJ et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 12, 1004-1012 (2011).
41. Solomon B, Felip E, Blackhall F et al. Overall and intracranial (IC) efficacy results and time to symptom deterioration in PROFILE 1014: 1st-line crizotinib vs. pemetrexed-platinum chemotherapy (PPC) in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC). Presented at: European Society for Medical Oncology (ESMO) Congress 2014. Madrid, Spain, 26-30 September 2014 (Abstract 1225O).
42. Ou SH, Tan J, Yen Y, Soo RA. ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway. Expert Rev. Anticancer Ther. 12, 447-456 (2012).
43. Rikova K, Guo A, Zeng Q et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190-1203 (2007).
44. Cai W, Li X, Su C et al. ROS1 fusions in Chinese patients with non-small-cell lung cancer. Ann. Oncol. 24, 1822-1827 (2013).
45. Morris SW, Naeve C, Mathew P et al. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 14, 2175-2188 (1997).
46. Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat. Rev. Cancer 6, 637-645 (2006).
47. Danilkovitch-Miagkova A, Zbar B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J. Clin. Invest. 109, 863-867 (2002).
48. Ou SH, Kwak EL, Siwak-Tapp C et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J. Thorac. Oncol. 6, 942-946 (2011).
49. Schnell P, Safferman AZ, Bartlett CH et al. Clinical presentation of hepatotoxicity-associated crizotinib in ALK-positive (ALK+) advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 30(Suppl.), Abstract 7598 (2012).
50. Sato Y, Fujimoto D, Shibata Y et al. Fulminant hepatitis following crizotinib administration for ALK-positive non-small-cell lung carcinoma. Jpn J. Clin. Oncol. 44(9), 872-875 (2014).
51. Ou SH, Azada M, Dy J, Stiber JA. Asymptomatic profound sinus bradycardia (heart rate
52. Weickhardt AJ, Doebele RC, Purcell WT et al. Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. Cancer 119, 2383-2390 (2013).
53. Doebele RC, Pilling AB, Aisner DL et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. 18, 1472-1482 (2012).
54. Katayama R, Shaw AT, Khan TM et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci. Transl. Med. 4, 120ra117 (2012).
55. Kim S, Kim TM, Kim DW et al. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. J. Thorac. Oncol. 8, 415-422 (2013).
56. Sequist LV, Gettinger S, Senzer NN et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J. Clin. Oncol. 28, 4953-4960 (2010).
57. Katayama R, Khan TM, Benes C et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc. Natl Acad. Sci. USA 108, 7535-7540 (2011).
58. Chen Z, Sasaki T, Tan X et al. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res. 70, 9827-9836 (2010).
59. Katayama R, Kobayashi Y, Friboulet L et al. Cabozantinib overcomes crizotinib resistance in ROS1 fusion positive cancer. Clin. Cancer Res. 4(120), 120ra17 (2014).
60. Gerber DE, Gandhi L, Costa DB. Management and future directions in non-small cell lung cancer with known activating mutations. Am. Soc. Clin. Oncol. Educ. Book 2014, e353-e365 (2014).
61. Shaw AT, Engelman JA. Ceritinib in ALK-rearranged non-small-cell lung cancer. N. Engl. J. Med. 370, 2537-2539 (2014).
62. Shaw AT, Kim DW, Mehra R et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N. Engl. J. Med. 370, 1189-1197 (2014).
63. Friboulet L, Li N, Katayama R et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 4, 662-673 (2014).
64. Camidge DR, Bazhenova L, Salgia R et al. Updated results of a first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies. J. Thorac. Oncol. 8(Suppl. 2), S296 (2013).